Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Respinova
Respinova Overview
Respinova has developed the PulseHaler, a noninvasive technology that aims to treat the core pathophysiology of chronic obstructive pulmonary disorder (COPD). The PulseHalers proprietary multi-frequency air pressure pulse technology is an easy-to-use treatment intended for patients diagnosed with COPD of all severity stages.
The companys technology was successfully validated in two clinical studies. The first study demonstrated PulseHalers ability to improve the lung function, exercise capacity, and quality of life of COPD patients. The second study demonstrated the technologys ability to deliver drugs more effectively to the lung periphery.
The PulseHaler stands alongside leading COPD drugs in managing the disease and enhancing the patients functional capacity and quality of life and has the potential to become a standard of care in COPD management.
The commercialization of PulseHaler was co-funded by the European Unions Horizon 2020 program. The device was granted an FDA 510(k) clearance in April 2021.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Respinova Climate Tech relevance
undefined
Latest News
No Data, yet.
Sorry, no content found under this section.
Apr 6, 2021
www.prnewswire.com
Respinova Granted FDA 510(k) Clearance for Pulsehaler™
#Customers
Jun 1, 2020
www.israel21c.org
COPD innovation may keep Covid patients off ventilators
#Customers
Nov 12, 2019
sciencebusiness.net
Israeli research breathes new life into EU battle against a life-threatening disorder
#Investment #Partners
Jun 19, 2018
globenewswire.com
Respinova Wins Chiesi Spain and Richi Entrepreneurs Second Call